Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Deffered Revenue: 2016-2023

Historic Non-Current Deffered Revenue for Seres Therapeutics (MCRB) over the last 8 years, with Dec 2023 value amounting to $95.4 million.

  • Seres Therapeutics' Non-Current Deffered Revenue rose 0.46% to $95.4 million in Q2 2024 from the same period last year, while for Jun 2024 it was $95.4 million, marking a year-over-year increase of 0.46%. This contributed to the annual value of $95.4 million for FY2023, which is 3.17% up from last year.
  • Per Seres Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $95.4 million for FY2023, which was up 3.17% from $92.4 million recorded in FY2022.
  • Over the past 5 years, Seres Therapeutics' Non-Current Deffered Revenue peaked at $95.4 million during FY2023, and registered a low of $85.6 million during FY2020.
  • In the last 3 years, Seres Therapeutics' Non-Current Deffered Revenue had a median value of $92.4 million in 2022 and averaged $91.6 million.
  • In the last 5 years, Seres Therapeutics' Non-Current Deffered Revenue decreased by 23.73% in 2019 and then climbed by 6.24% in 2022.
  • Over the past 5 years, Seres Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $89.1 million in 2019, then fell by 3.97% to $85.6 million in 2020, then grew by 1.67% to $87.0 million in 2021, then increased by 6.24% to $92.4 million in 2022, then climbed by 3.17% to $95.4 million in 2023.